Skip to main content

Additional Articles by the Author

F. Randy Vogenberg, PhD, FASHP
Business, Original Research
Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers
Burton S. Brodsky, MD; Gary M. Owens, MD; Dennis J. Scotti, PhD, MBA; Keith A. Needham, BS; Christina L. Cool, MPH
Stakeholder Perspective
Economic Impact of Using Tests to Guide the Treatment of Patients with Ovarian Cancer
F. Randy Vogenberg, PhD, RPh
Read More
Business
Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis
Kumar Mukherjee, PhD; Khalid M. Kamal, PhD
Stakeholder Perspective
Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes
F. Randy Vogenberg, RPh, PhD
Read More
Industry Trends
Top 10 Healthcare Market Trends in 2017
John Santilli, MBA, and F. Randy Vogenberg, RPh, PhD
Read More
Industry Trends
Employer Perspectives on a Specialty Drug Step-Therapy Program Evaluation
Read More
Business
Hospital and Health Plan Partnerships: The Affordable Care Act’s Impact on Promoting Health and Wellness
Stakeholder Perspective
Measurable Clarity in Healthcare Is Needed So Those Who Use the System Could Achieve a State of Well-Being
Read More
Industry Trends
Top Healthcare Market Trends in 2016
Read More
Perspectives
Employers Engaged in Benefit Design Innovation: Long-Term Trends in a 2015 National Survey
Read More
Clinical
Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment
Stakeholder Perspective
Closing Gaps in Health Plan Performance with Stakeholder Collaboration
Read More
Perspectives
Guiding Employer Management of Specialty Drugs
Read More
Business
The Cost of Unintended Pregnancies for Employer-Sponsored Health Insurance Plans
Stakeholder Perspective
A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design
Read More
Page 2 of 5
Results 11 - 20 of 45